Skip to main content
Clinical Trials/NCT04700033
NCT04700033
Completed
Not Applicable

Immersive Virtual Reality for Chronic Neuropathic Pain After Spinal Cord Injury: A Feasibility Trial

Icahn School of Medicine at Mount Sinai1 site in 1 country23 target enrollmentJuly 17, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Spinal Cord Injuries
Sponsor
Icahn School of Medicine at Mount Sinai
Enrollment
23
Locations
1
Primary Endpoint
Neuropathic Pain Symptom Inventory (NPSI)
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The aim of this study is to provide critical information about the efficacy of Immersive Virtual Reality (IVR) to decrease the experience of neuropathic pain in the upper and lower extremities of people with a spinal cord injury.

Detailed Description

When a spinal cord injury occurs, the spinal somatosensory circuit is thought to generate aberrant nociceptive impulses that the brain interprets as pain. Neuropathic pain (NP) affects 40 to 70% of people with SCI and is a very disabling clinical condition. Many treatment options have been offered, but provide limited effects, leaving people with SCI with a reduced quality of life. The study team believes that Immersive Virtual Reality (IVR) neurorehabilitation has the potential to be an effective treatment for chronic neuropathic pain. For this reason, the objective of this study is to evaluate the feasibility of using a virtual reality device to decrease chronic neuropathic pain in individuals with spinal cord injury.

Registry
clinicaltrials.gov
Start Date
July 17, 2019
End Date
May 5, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

David Putrino

Director of Rehabilitation Innovation

Icahn School of Medicine at Mount Sinai

Eligibility Criteria

Inclusion Criteria

  • Spinal cord injury survivors (chronic only)
  • Presence of neuropathic pain at or below SCI level for at least 6 months following trauma or disease of the spinal cord
  • A pain intensity of at least 2 out of 10 in the numerical pain rating scale (NPRS) test at baseline
  • Stable pharmacological treatment for at least 4 weeks prior to the study and throughout the trial

Exclusion Criteria

  • Psychiatric or other neurological disorders (Participants will not be excluded for having a SCI, if they score 0-30 points on the BDI, or if they report having anxiety)
  • Head injuries causing cognitive or visual impairment
  • Severe vertigo

Outcomes

Primary Outcomes

Neuropathic Pain Symptom Inventory (NPSI)

Time Frame: Up to 10 Weeks

Neuropathic Pain Symptom Inventory (NPSI): This scale was developed to assess both the quantitative and qualitative qualities of neuropathic pain (NP). It includes 12 items, assessing spontaneous pain, brief attacks of pain, provoked pain and abnormal sensations in the painful area. This is a sensitive tool for measuring changes in neuropathic pain after a therapeutic intervention. Total score range for NPSI is 0-100, higher scores indicate more severity.

Secondary Outcomes

  • Spinal Cord Independence Measure (SCIM III)(Up to 10 Weeks)
  • Immersive Tendencies Questionnaire (ITQ)(Up to 10 Weeks)
  • User Experience Score (UES)(14 Days)
  • Numerical Pain Rating Scale (NPRS)(16 Days)
  • Beck Depression Inventory (BDI)(Up to 10 Weeks)
  • Patient's Global Impression of Change (PGIC)(Up to 10 Weeks)
  • UQO- Presence Questionnaire (UPO-PQ)(16 Days)
  • Neuropathic Pain Scale (NPS)(Up to 10 Weeks)

Study Sites (1)

Loading locations...

Similar Trials